Dianthus Therapeutics Banner

Release Details

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

Dianthus Therapeutics to Participate in Upcoming Investor Healthcare Conferences in November

November 1, 2023 at 4:32 PM EDT

NEW YORK and WALTHAM, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the Company’s senior management team will participate in the following upcoming investor healthcare conferences during the month of November:

  • Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference on November 6 in New York City
  • Jefferies 2023 London Healthcare Conference on November 14-15 in London
  • Evercore ISI 6th Annual HealthCONx Conference on November 28-29 in Miami

About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Media Contact
Peg Rusconi
Verge Scientific Communications